These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28287644)

  • 1. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation.
    Dotoli GM; De Santis GC; Orellana MD; de Lima Prata K; Caruso SR; Fernandes TR; Rensi Colturato VA; Kondo AT; Hamerschlak N; Simões BP; Covas DT
    Bone Marrow Transplant; 2017 Jun; 52(6):859-862. PubMed ID: 28287644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.
    von Dalowski F; Kramer M; Wermke M; Wehner R; Röllig C; Alakel N; Stölzel F; Parmentier S; Sockel K; Krech M; Schmitz M; Platzbecker U; Schetelig J; Bornhäuser M; von Bonin M
    Stem Cells; 2016 Feb; 34(2):357-66. PubMed ID: 26418955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.
    Ball LM; Bernardo ME; Roelofs H; van Tol MJ; Contoli B; Zwaginga JJ; Avanzini MA; Conforti A; Bertaina A; Giorgiani G; Jol-van der Zijde CM; Zecca M; Le Blanc K; Frassoni F; Egeler RM; Fibbe WE; Lankester AC; Locatelli F
    Br J Haematol; 2013 Nov; 163(4):501-9. PubMed ID: 23992039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
    Prasad VK; Lucas KG; Kleiner GI; Talano JA; Jacobsohn D; Broadwater G; Monroy R; Kurtzberg J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):534-41. PubMed ID: 20457269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
    Sánchez-Guijo F; Caballero-Velázquez T; López-Villar O; Redondo A; Parody R; Martínez C; Olavarría E; Andreu E; Prósper F; Díez-Campelo M; Regidor C; Villaron E; López-Corral L; Caballero D; Cañizo MC; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1580-5. PubMed ID: 24952358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
    van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
    Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
    Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.
    Introna M; Lucchini G; Dander E; Galimberti S; Rovelli A; Balduzzi A; Longoni D; Pavan F; Masciocchi F; Algarotti A; Micò C; Grassi A; Deola S; Cavattoni I; Gaipa G; Belotti D; Perseghin P; Parma M; Pogliani E; Golay J; Pedrini O; Capelli C; Cortelazzo S; D'Amico G; Biondi A; Rambaldi A; Biagi E
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):375-81. PubMed ID: 24321746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up.
    Niu JW; Li Y; Xu C; Sheng H; Tian C; Ning H; Hu J; Chen J; Li B; Wang J; Lou X; Liu N; Su Y; Sun Y; Qiao Z; Wang L; Zhang Y; Lan S; Xie J; Ren J; Peng B; Wang S; Shi Y; Zhao L; Zhang Y; Chen H; Zhang B; Hu L
    Front Immunol; 2024; 15():1436653. PubMed ID: 39211037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
    Herrmann R; Sturm M; Shaw K; Purtill D; Cooney J; Wright M; Phillips M; Cannell P
    Int J Hematol; 2012 Feb; 95(2):182-8. PubMed ID: 22183779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study.
    Muroi K; Miyamura K; Okada M; Yamashita T; Murata M; Ishikawa T; Uike N; Hidaka M; Kobayashi R; Imamura M; Tanaka J; Ohashi K; Taniguchi S; Ikeda T; Eto T; Mori M; Yamaoka M; Ozawa K
    Int J Hematol; 2016 Feb; 103(2):243-50. PubMed ID: 26608364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).
    Bader P; Kuçi Z; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; von Luettichau I; Herter-Sprie G; Uddin MA; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Klingebiel T; Bonig H; Kuçi S
    Bone Marrow Transplant; 2018 Jul; 53(7):852-862. PubMed ID: 29379171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
    Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.
    Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
    Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
    BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.